{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:25:47Z","timestamp":1790270747511,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,7]]},"DOI":"10.7759\/cureus.44864","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T23:00:57Z","timestamp":1694127657000},"source":"Crossref","is-referenced-by-count":2,"title":["Development of Erythema Nodosum After Olaparib Treatment in a Patient With Recurrent Breast Cancer and BRCA2 Mutation: A Case Report"],"prefix":"10.7759","author":[{"given":"Masayuki","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihito","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirona","family":"Banno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/10.7.705","article-title":"BRCA1 and BRCA2 and the genetics of breast and ovarian cancer","volume":"10","author":"Welcsh PL","year":"2001","unstructured":"Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001, 10:705-13. 10.1093\/hmg\/10.7.705","journal-title":"Hum Mol Genet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson M","year":"2017","unstructured":"Robson M, Im SA, Senkus E, et al.. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017, 377:523-33. 10.1056\/NEJMoa1706450","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt AN","year":"2021","unstructured":"Tutt AN, Garber JE, Kaufman B, et al.. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021, 384:2394-405. 10.1056\/NEJMoa2105215","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine E","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, et al.. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017, 18:1274-84. 10.1016\/S1470-2045(17)30469-2","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono J","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, et al.. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020, 382:2091-102. 10.1056\/NEJMoa1911440","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan T","year":"2019","unstructured":"Golan T, Hammel P, Reni M, et al.. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019, 381:317-27. 10.1056\/NEJMoa1903387","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2007.02.009","article-title":"Erythema nodosum","volume":"26","author":"Requena L","year":"2007","unstructured":"Requena L, S\u00e1nchez Yus E. Erythema nodosum. Semin Cutan Med Surg. 2007, 26:114-25. 10.1016\/j.sder.2007.02.009","journal-title":"Semin Cutan Med Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.02.017","article-title":"Two decades beyond BRCA1\/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy","volume":"137","author":"Walsh CS","year":"2015","unstructured":"Walsh CS. Two decades beyond BRCA1\/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol. 2015, 137:343-50. 10.1016\/j.ygyno.2015.02.017","journal-title":"Gynecol Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O'Connor MJ","year":"2015","unstructured":"O'Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015, 60:547-60. 10.1016\/j.molcel.2015.10.040","journal-title":"Mol Cell"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200003)43:3<584::AID-ANR15>3.0.CO;2-6","article-title":"Erythema nodosum: etiologic and predictive factors in a defined population","volume":"43","author":"Garc\u00eda-Porr\u00faa C","year":"2000","unstructured":"Garc\u00eda-Porr\u00faa C, Gonz\u00e1lez-Gay MA, V\u00e1zquez-Caruncho M, et al.. Erythema nodosum: etiologic and predictive factors in a defined population. Arthritis Rheum. 2000, 43:584-92. 10.1002\/1529-0131(200003)43:3&lt;584::AID-ANR15&gt;3.0.CO;2-6","journal-title":"Arthritis Rheum"},{"key":"ref11","article-title":"Erythema nodosum: an evaluation of 100 cases","volume":"25","author":"Mert A","year":"2007","unstructured":"Mert A, Kumbasar H, Ozaras R, Erten S, Tasli L, Tabak F, Ozturk R. Erythema nodosum: an evaluation of 100 cases. Clin Exp Rheumatol. 2007, 25:563-70.","journal-title":"Clin Exp Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00592-w","article-title":"Erythema nodosum: a practical approach and diagnostic algorithm","volume":"22","author":"P\u00e9rez-Garza DM","year":"2021","unstructured":"P\u00e9rez-Garza DM, Chavez-Alvarez S, Ocampo-Candiani J, Gomez-Flores M. Erythema nodosum: a practical approach and diagnostic algorithm. Am J Clin Dermatol. 2021, 22:367-78. 10.1007\/s40257-021-00592-w","journal-title":"Am J Clin Dermatol"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.2340\/0001555562265266","article-title":"Suppression of erythema nodosum by indomethacin","volume":"62","author":"Ubogy Z","year":"1982","unstructured":"Ubogy Z, Persellin RH. Suppression of erythema nodosum by indomethacin. Acta Derm Venereol. 1982, 62:265-6.","journal-title":"Acta Derm Venereol"},{"key":"ref14","article-title":"Potassium iodide in the treatment of erythema nodosum and nodular vasculitis","volume":"117","author":"Horio T","year":"1981","unstructured":"Horio T, Imamura S, Danno K, Ofuji S. Potassium iodide in the treatment of erythema nodosum and nodular vasculitis. Arch Dermatol. 1981, 117:29-31.","journal-title":"Arch Dermatol"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.5070\/D3204022376","article-title":"Erythema nodosum - a review of an uncommon panniculitis","volume":"20","author":"Blake T","year":"2014","unstructured":"Blake T, Manahan M, Rodins K. Erythema nodosum - a review of an uncommon panniculitis. Dermatol Online J. 2014, 20:22376.","journal-title":"Dermatol Online J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/BF02114402","article-title":"Erythema nodosum and Hodgkin's disease","volume":"9","author":"Taillan B","year":"1990","unstructured":"Taillan B, Ferrari E, Fuzibet JG, Vinti H, Pesce A, Dujardin P. Erythema nodosum and Hodgkin's disease. Clin Rheumatol. 1990, 9:397-8. 10.1007\/BF02114402","journal-title":"Clin Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000000233","article-title":"FDG PET\/CT showing erythema nodosum associated with tuberculous lymphadenitis","volume":"38","author":"Chen X","year":"2013","unstructured":"Chen X, Lu H, Gao Y. FDG PET\/CT showing erythema nodosum associated with tuberculous lymphadenitis. Clin Nucl Med. 2013, 38:992-3. 10.1097\/RLU.0000000000000233","journal-title":"Clin Nucl Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9529821","article-title":"A novel adverse event associated with olaparib therapy in a patient with metastatic breast cancer","volume":"2018","author":"Wheelden M","year":"2018","unstructured":"Wheelden M, Cream L, Sivik J, Robson M. A novel adverse event associated with olaparib therapy in a patient with metastatic breast cancer. Case Rep Oncol Med. 2018, 2018:9529821. 10.1155\/2018\/9529821","journal-title":"Case Rep Oncol Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00353-3","article-title":"Anastrozole-induced dermatitis: report of a woman with an anastrozole-associated dermatosis and a review of aromatase inhibitor-related cutaneous adverse events","volume":"10","author":"Kim YJ","year":"2020","unstructured":"Kim YJ, Cohen PR. Anastrozole-induced dermatitis: report of a woman with an anastrozole-associated dermatosis and a review of aromatase inhibitor-related cutaneous adverse events. Dermatol Ther (Heidelb). 2020, 10:221-9. 10.1007\/s13555-020-00353-3","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9518-7","article-title":"Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature","volume":"106","author":"Jhaveri K","year":"2007","unstructured":"Jhaveri K, Halperin P, Shin SJ, Vahdat L. Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature. Breast Cancer Res Treat. 2007, 106:315-8. 10.1007\/s10549-007-9518-7","journal-title":"Breast Cancer Res Treat"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/174984-development-of-erythema-nodosum-after-olaparib-treatment-in-a-patient-with-recurrent-breast-cancer-and-brca2-mutation-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:34Z","timestamp":1707509074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/174984-development-of-erythema-nodosum-after-olaparib-treatment-in-a-patient-with-recurrent-breast-cancer-and-brca2-mutation-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.44864","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,7]]}}}